Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the expression of the fatty acid transporter CD36

FEBS Lett. 2021 Oct;595(19):2493-2503. doi: 10.1002/1873-3468.14193. Epub 2021 Sep 27.

Abstract

Nonalcoholic fatty liver disease (NAFLD) can lead to hepatocellular carcinoma (HCC). The level of the transcription factor SOX2 correlates with HCC progression, but its role in fat accumulation remains unclear. Here, a high-fat diet, with and without fructose, significantly upregulated SOX2 in murine liver tissue. Treatment with free fatty acids (FFAs) and fructose upregulated SOX2 in murine FL83B hepatocytes. SOX2 overexpression or knockdown regulated triglyceride synthesis and lipid accumulation after FFA stimulation. CD36, a fatty acid transporter, and Yes-associated protein (YAP), a downstream molecule of the Hippo signaling pathway, were upregulated by FFA/fructose in vivo and in vitro. Transcriptional regulation of CD36 by SOX2 suggested the involvement of CD36 in SOX2-mediated hepatic steatosis. Thus, SOX2 may be a target to prevent NAFLD development.

Keywords: Yes-associated protein; cluster of differentiation 36; hepatocyte; nonalcoholic fatty liver disease; sex-determining region Y-box 2; tumor necrosis factor-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD36 Antigens / metabolism*
  • Disease Progression
  • Gene Expression Regulation*
  • Mice
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • SOXB1 Transcription Factors / metabolism*

Substances

  • CD36 Antigens
  • SOXB1 Transcription Factors